Table I.
Transition probabilities between glioblastoma disease states.
| Transition probabilities | Baseline value | Lower limit | Upper limit |
|---|---|---|---|
| BEV+TMZ group | |||
| PPFS-PFS-1 | 0.81 | 0.65 | 0.97 |
| PPFS-PD-1 | 0.13 | 0.11 | 0.16 |
| PPFS-death-1 | 0.06 | 0.05 | 0.08 |
| PPD-PD-1 | 0.89 | 0.71 | 1.00 |
| PPD-death-1 | 0.11 | 0.09 | 0.14 |
| TMZ group | |||
| PPFS-PFS-2 | 0.64 | 0.51 | 0.77 |
| PPFS-PD-2 | 0.27 | 0.22 | 0.32 |
| PPFS-death-2 | 0.09 | 0.07 | 0.10 |
| PPD-PD-2 | 0.88 | 0.71 | 1.00 |
| PPD-death-2 | 0.12 | 0.09 | 0.14 |
BEV, bevacizumab; TMZ, temozolomide; PFS, progression-free survival; PD, progressive disease.